Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Hematology Reports
|
May 16, 2012
Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma
Stefano Luminari, Antonella Montanini, Massimo Federico
Expert Review of Hematology
|
November 19, 2010
Prognostic tools in follicular lymphomas
Stefano Luminari, Maria Christina Cox, Antonella Montanini, et al.
Leukemia & Lymphoma
|
January 7, 2006
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi
Nicola Di Renzo, Maura Brugiatelli, Antonella Montanini, et al.
Hematological Oncology
|
July 27, 2007
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy
Stefano Luminari, Marina Cesaretti, Ivan Rashid, et al.
European Journal of Haematology
|
February 3, 2006
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study
Massimo Federico, Stefano Luminari, Paolo G Gobbi, et al.
Leukemia & Lymphoma
|
September 16, 2011
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial
Fortunato Morabito, Stefan Hohaus, Corrado Mammi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 10, 2010
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
Nicola Di Renzo, Antonella Montanini, Donato Mannina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi
Teodoro Chisesi, Monica Bellei, Stefano Luminari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2009
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico, Stefano Luminari, Emilio Iannitto, et al.
British Journal of Haematology
|
March 5, 2011
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study
Emilio Iannitto, Fortunato Morabito, Salvatrice Mancuso, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Hematology Reports
|
May 16, 2012
Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma
Stefano Luminari, Antonella Montanini, Massimo Federico
Expert Review of Hematology
|
November 19, 2010
Prognostic tools in follicular lymphomas
Stefano Luminari, Maria Christina Cox, Antonella Montanini, et al.
Leukemia & Lymphoma
|
January 7, 2006
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi
Nicola Di Renzo, Maura Brugiatelli, Antonella Montanini, et al.
Hematological Oncology
|
July 27, 2007
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy
Stefano Luminari, Marina Cesaretti, Ivan Rashid, et al.
European Journal of Haematology
|
February 3, 2006
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study
Massimo Federico, Stefano Luminari, Paolo G Gobbi, et al.
Leukemia & Lymphoma
|
September 16, 2011
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial
Fortunato Morabito, Stefan Hohaus, Corrado Mammi, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 10, 2010
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
Nicola Di Renzo, Antonella Montanini, Donato Mannina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi
Teodoro Chisesi, Monica Bellei, Stefano Luminari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2009
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
Massimo Federico, Stefano Luminari, Emilio Iannitto, et al.
British Journal of Haematology
|
March 5, 2011
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study
Emilio Iannitto, Fortunato Morabito, Salvatrice Mancuso, et al.
Page
of 1